Literature DB >> 20425426

What is the best treatment for children with limited-stage Hodgkin lymphoma?

Frank G Keller1, Sharon M Castellino, James B Nachman.   

Abstract

Limited-stage Hodgkin lymphoma remains a challenging problem for pediatric oncologists. Published and investigative treatment regimens represent varied approaches to balance the excellent overall and event-free survival with the substantial potential for long-term sequelae of effective treatment modalities. Regimens incorporating low-dose radiation to smaller fields and chemotherapy that limits cumulative exposure to the agents most closely associated with long-term complications have been shown to be effective for most patients. Investigative approaches to optimize overall therapy focus on identifying which patients require more or less therapy. A recent example is the use of response-based therapy as a means of limiting or omitting radiation for those with an early, rapid response to chemotherapy. Biologic markers that influence risk for treatment failure or treatment-related toxicities have been only minimally defined. This paper reviews recently published treatment regimens for children and adolescents and presents some considerations for choosing a treatment approach for individual patients.

Entities:  

Mesh:

Year:  2009        PMID: 20425426     DOI: 10.1007/s11899-009-0019-0

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  33 in total

1.  PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.

Authors:  Lale Kostakoglu; Morton Coleman; John P Leonard; Ichiei Kuji; Holly Zoe; Stanley J Goldsmith
Journal:  J Nucl Med       Date:  2002-08       Impact factor: 10.057

2.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

Authors:  Martin Hutchings; Annika Loft; Mads Hansen; Lars Møller Pedersen; Thora Buhl; Jesper Jurlander; Simon Buus; Susanne Keiding; Francesco D'Amore; Anne-Marie Boesen; Anne Kiil Berthelsen; Lena Specht
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

3.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

4.  Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial.

Authors:  U Rühl; M Albrecht; K Dieckmann; H Lüders; H Marciniak; D Schellenberg; L Wickmann; W Dörffel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-12-01       Impact factor: 7.038

5.  Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age. An Italian (AIEOP) multicenter study on 215 patients.

Authors:  V Vecchi; S Pileri; R Burnelli; N Bontempi; A Comelli; A M Testi; M Carli; G Sotti; D Rosati; M T Di Tullio
Journal:  Cancer       Date:  1993-09-15       Impact factor: 6.860

6.  Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy.

Authors:  James B Nachman; Richard Sposto; Philip Herzog; Gerald S Gilchrist; Suzanne L Wolden; John Thomson; Marshall E Kadin; Paul Pattengale; P Charlton Davis; Raymond J Hutchinson; Keith White
Journal:  J Clin Oncol       Date:  2002-09-15       Impact factor: 44.544

7.  Thyroid dysfunction after radiotherapy in children with Hodgkin's disease.

Authors:  L S Constine; S S Donaldson; I R McDougall; R S Cox; M P Link; H S Kaplan
Journal:  Cancer       Date:  1984-02-15       Impact factor: 6.860

8.  Breast cancer and other second neoplasms after childhood Hodgkin's disease.

Authors:  S Bhatia; L L Robison; O Oberlin; M Greenberg; G Bunin; F Fossati-Bellani; A T Meadows
Journal:  N Engl J Med       Date:  1996-03-21       Impact factor: 91.245

9.  Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma.

Authors:  Christine Mauz-Körholz; Stephanie Gorde-Grosjean; Dirk Hasenclever; Ananth Shankar; Wolfgang Dörffel; W Hamish Wallace; Günther Schellong; Alain Robert; Dieter Körholz; Odile Oberlin; Georgina W Hall; Judith Landman-Parker
Journal:  Cancer       Date:  2007-07-01       Impact factor: 6.860

10.  XRCC1 and glutathione-S-transferase gene polymorphisms and susceptibility to radiotherapy-related malignancies in survivors of Hodgkin disease.

Authors:  Ann C Mertens; Pauline A Mitby; Gretchen Radloff; Irene M Jones; John Perentesis; William R Kiffmeyer; Joseph P Neglia; Anna Meadows; John D Potter; Debra Friedman; Yutaka Yasui; Leslie L Robison; Stella M Davies
Journal:  Cancer       Date:  2004-09-15       Impact factor: 6.921

View more
  2 in total

1.  Early interim FDG PET/CT prediction of treatment response and prognosis in pediatric Hodgkin disease-added value of low-dose CT.

Authors:  Anat Ilivitzki; Lea Radan; Miriam Ben-Arush; Ora Israel; Ayelet Ben-Barak
Journal:  Pediatr Radiol       Date:  2012-11-14

2.  Late bone and soft tissue sequelae of childhood radiotherapy. Relevance of treatment age and radiation dose in 146 children treated between 1970 and 1997.

Authors:  W Dörr; S Kallfels; T Herrmann
Journal:  Strahlenther Onkol       Date:  2013-05-25       Impact factor: 3.621

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.